| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1373841 | Bioorganic & Medicinal Chemistry Letters | 2006 | 6 Pages |
Abstract
A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC50s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP.
Graphical abstractA novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC50 ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Shengde Wu, Andrew Fluxe, Jim Sheffer, John M. Janusz, Benjamin E. Blass, Ron White, Chris Jackson, Richard Hedges, Michael Murawsky, Bin Fang, Gina M. Fadayel, Michelle Hare, Laurent Djandjighian,